戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er neurologic deterioration in patients with leptomeningeal metastasis.
2 arding methods of diagnosis and treatment of leptomeningeal metastasis.
3 F-liberating proteases that could facilitate leptomeningeal metastasis.
4 ion, perivascular niche micrometastasis, and leptomeningeal metastasis.
5 upting the blood-brain barrier and promoting leptomeningeal metastasis.
6 nd patient-derived humanized mouse models of leptomeningeal metastasis.
7 er neurologic deterioration in patients with leptomeningeal metastasis.
8 e systemic therapy may benefit patients with leptomeningeal metastasis and obviate the need for intra
9  include central nervous system prophylaxis, leptomeningeal metastasis, and common hematologic compli
10 ts increasingly utilized in the treatment of leptomeningeal metastasis are targeted mAbs such as ritu
11 tilized intra-CSF agents in the treatment of leptomeningeal metastasis are targeted monoclonal antibo
12                                Breast cancer leptomeningeal metastasis (BCLM), where tumour cells gro
13 lide cerebrospinal fluid (CSF) flow study if leptomeningeal metastasis-directed therapy is being cons
14 ed therapeutically beneficial in suppressing leptomeningeal metastasis in these preclinical models.
15                                Evaluation of leptomeningeal metastasis includes contrast-enhanced bra
16 single most important aspect to diagnosis of leptomeningeal metastasis is considering and pursuing th
17                        Although treatment of leptomeningeal metastasis is palliative with median pati
18                        Although treatment of leptomeningeal metastasis is palliative with median pati
19 ndard-of-care radiotherapy for patients with leptomeningeal metastasis (LM) from solid tumors.
20                                              Leptomeningeal metastasis (LM) represents a devastating
21                                              Leptomeningeal metastasis (LM), or spread of cancer to t
22 neic lung cancer, breast cancer and melanoma leptomeningeal-metastasis mouse models.
23                                              Leptomeningeal metastasis occurs in approximately 3-5% o
24                                              Leptomeningeal metastasis occurs in approximately 5% of
25                                 Treatment of leptomeningeal metastasis often requires involved-field
26                     We molecularly dissected leptomeningeal metastasis, or spread of cancer to the ce
27 cerebrospinal-fluid-filled leptomeninges, or leptomeningeal metastasis, represents a fatal complicati
28                                   Staging of leptomeningeal metastasis should include contrast-enhanc
29 survival of 2-3 months (15% of patients with leptomeningeal metastasis survive 1 year), treatment may
30 iew of methods of diagnosis and treatment of leptomeningeal metastasis was performed.